Study evaluates use of extended-release niacin

03/28/2012 |

About 3.5% of patients with hyperlipidemia who used a combination of extended-release niacin and ezetimibe/simvastatin met the criteria for new onset diabetes at 64 weeks, compared with 2.6% in those taking E/S alone, according to a study in Diabetes Care. The researchers said those taking niacin had increased fasting glucose levels, but the cases went away without intervention.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA